Veristat Welcomes Three New Leaders to Executive Team

Veristat has added three seasoned leaders to its executive team. 
 
Elizabeth R. Madichie, Ph.D., joins Veristat as executive vice president of Global Regulatory Affairs, responsible for all aspects of the development and implementation of the company’s global regulatory services. Madichie has more than 25 years of experience leading global functions in pharmaceutical, biotech, and CRO organizations, setting strategic priorities, and establishing best practices across regulatory affairs, pharmacovigilance, medical information, market access, and product development in multiple therapeutic areas. She possesses expert knowledge of the regulatory and commercial environments and legislative framework for biopharmaceuticals worldwide, enabling the development and commercialization of novel and established products and services across more than 160 countries. Madichie currently serves as past president and board director of The Organization of Professionals in Regulatory Affairs (TOPRA).
 
Natalia Grassis has been hired as executive vice president of Global Clinical Operations and Delivery to oversee Veristat’s end-to-end clinical trial operations. An accomplished business executive with more than two decades of experience in leadership roles at global clinical research organizations and biotech companies, Grassis brings extensive knowledge across all phases of clinical development spanning a number of therapeutic categories, including infectious disease (COVID-19), gene therapy, rare disease, oncology, and CNS. Her deep experience conducting innovative business process improvement initiatives and driving cutting-edge research with patient-centered virtual clinical trials has resulted in accelerated drug development timelines for clients. 
 
Nan Shao, Ph.D., has been named executive vice president of Global Operations to manage and oversee the clinical trial data, analytics, and reporting organization across all regions. A successful business leader, clinical research professional, and statistician with 20 years of pharmaceutical industry experience and 10 years leading global biometrics operations and strategic divisions, Nan brings significant expertise in analytics strategy, biostatistics, statistical programming, data management, pharmacokinetics, and data standards. She is highly skilled in the clinical development life cycle across a range of therapeutic areas, collaborating with clients to achieve their operational and business goals.

The appointments reflect Veristat’s rapid rate of global growth supporting sponsors in overcoming the challenges of operating in complex and highly regulated clinical environments. 
 
A scientific-minded global clinical research organization (CRO), Veristate enables sponsors to solve the challenges associated with accelerating therapies through clinical development to regulatory approval and commercialization. With more than 29 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.